榴莲视频

Charles Bankhead

Charles Bankhead

Authors >

Charles Bankhead

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. His career spans more than 30 years, including a decade with Medical World News, a leading medical trade magazine of its time. He had a long and successful freelance career before joining 榴莲视频 in 2007. Charles graduated with honors from Texas Tech University, receiving a BA in journalism, and completed a master's degree in mass communication, with specialization in health communication, also at Texas Tech.

Connect:

email image

Latest from Charles Bankhead

FDA APPROVED revumenib (Revuforj) over a computer rendering of leukemia cells.

FDA Approves First Menin Inhibitor for Acute Leukemia

Complete responses in 21% of patients treated with single-agent revumenib

A close up photo of a neurofibroma.

MEK Inhibitor Scores Big Win in Adults, Children With Neurofibromatosis Type 1

More than 40% of adults, half of children met response criteria, majority of responses durable

Onco Break over a computer rendering of a cancer cell.

Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer

News, features, and commentary about cancer-related issues

IKCS over a photo of Omni Louisville in Louisville, KY.

Targeted Combination Shows Promise in Metastatic Kidney Cancer

Other IKCS news: closer look at belzutifan safety, challenges of triplet therapies for RCC

IKCS over a photo of Omni Louisville in Louisville, KY.

Large, Grade 4 Kidney Tumors Pose Risk of Early Cancer-Specific Mortality

Possible guidance for use of adjuvant immunotherapy in high-risk, non-metastatic disease

IKCS over a photo of Omni Louisville in Louisville, KY.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

Better OS, PFS, response rate, but newer combination strategies not included

IKCS over a photo of Omni Louisville in Louisville, KY.

Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control

More IKCS news: Long-term survival benefit with nivolumab/ipilimumab, disease-slowing surgery

IKCS over a photo of Omni Louisville in Louisville, KY.

Higher Risk of Kidney Cancer Recurrence After Ablative Therapy

Low rate of recurrence with surgery or nonsurgical options, but data can inform decisions

IKCS over a photo of Omni Louisville in Louisville, KY.

CAR T-Cell Therapy for Kidney Cancer Builds on Efficacy Record

Confirmed responses in one-fourth to one-third of patients with refractory disease

A computer rendering of CAR-T cells attacking hodgkin lymphoma cells.

Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid Tumors

Molecular heterogeneity, an immunosuppressive microenvironment, less accessible targets

2

鈥�